Nathan A. Beaver Esq.

Foley & Lardner LLP
Beaver, Nathan

Nathan A. Beaver is a partner and food and drug lawyer with Foley & Lardner LLP, and serves as a member of the advisory board of Bloomberg BNA's Life Sciences Law & Industry Report. His practice focuses on the representation of manufacturers whose products and activities are regulated by the Food and Drug Administration (FDA), Drug Enforcement Administration (DEA), and the Federal Trade Commission (FTC). He advises clients on regulatory issues affecting prescription and over-the-counter drug products (including animal drugs), medical devices, dietary supplements, cosmetics, and foods with special emphasis on the strategic considerations involving the approval process and patent and exclusivity issues related to the Hatch-Waxman Act. Mr. Beaver is a member of the firm’s Government & Public Policy and FDA Practices, and the Food & Beverage Industry and Life Sciences Industry Teams.

Mr. Beaver also has significant experience in FDA and Hatch-Waxman cases involving drug approvals, withdrawals and other types of litigation involving FDA regulated products.

Mr. Beaver received his B.A. from the University of Arizona, and his J.D. from Georgetown University Law Center.